KOSPIBiotech & Pharma009290

Kwangdong Pharmaceutical

₩6,060▼ 0.98%2026-11-18 close
Market Cap
₩301.8B
Turnover
₩600M
Volume
110K
Shares out.
49.8M
PER
24.8×
PBR
0.5×
EPS
₩253
Dividend Yield
1.59%

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q4–2026Q3) · Dividend yield is based on ₩100 per share · Prices as of the 2026-11-18 close

01

Report overview

Sales up, profits thin at Kwangdong Pharmaceutical

Kwangdong Pharmaceutical's revenue has grown for three straight years since 2023, yet its operating margin has stayed below 2%, so whether sales growth turns into profit is the key question.

  1. 1

    Q3 2026 revenue was KRW 460.6 billion, up 3.6% year on year, while operating profit was KRW 7.04 billion, down 35.2%. The figures were preliminary and released on November 11, 2026.

  2. 2

    Net income attributable to parent shareholders fell 48.2% in 2025 to KRW 21 billion, and the sum over the latest four quarters is KRW 12.2 billion. Q3 2026 parent net income of KRW 1.15 billion was down 89.3% year on year.

  3. 3

    A merchandise-heavy business model is seen as the main constraint on profitability, with about 70% of 2025 consolidated revenue coming from products sourced from outside.

  4. 4

    Operating cash flow moved from -KRW 11.7 billion in 2023 and -KRW 12.2 billion in 2024 to KRW 82.3 billion in 2025, while the debt ratio eased to 85.5% at end-2025 from 89.3%.

  5. 5

    The share price sits below book value attributable to parent shareholders, while earnings-based multiples look high because profit has shrunk. The gap between the two depends on whether earnings recover.

02

Business structure

Kwangdong Pharmaceutical sells pharmaceuticals as well as beverages and bottled water, and most of its consolidated revenue comes from products it sources from outside rather than makes itself.

Of the 2025 consolidated revenue of KRW 1.66 trillion, merchandise sales were KRW 1.16 trillion, about 70%, while self-manufactured product sales were KRW 486.9 billion, according to Hansbiz. Merchandise made up 56.6% of standalone sales in the first half of 2026, according to Biotimes.

The largest item is Jeju Samdasoo, which sold KRW 160.5 billion in the first half of 2026 and accounts for more than 30% of total revenue, according to press coverage. Other key products include Vita500, corn silk tea, Hovenia tea, and Cheongsimwon and Ssanghwatang over-the-counter medicines.

In drinks, the company competes with the Bacchus brand from a rival pharmaceutical group; in the first half of 2026 Bacchus sold KRW 59.5 billion and Vita500 KRW 57.8 billion, according to Dailypharm. R&D spending was KRW 6.98 billion in the first half of 2026, or 1.4% of sales, according to Biotimes.

Coverage notes that this merchandise-centered model supports sales expansion but limits margin improvement because of cost and promotion burdens, according to Hansbiz.

Per the 2022 business report, general products are sold directly to pharmacies, while hospital products are supplied directly to university and general hospitals.

03

Earnings trend

Quarterly revenue · Operating profit
RevenueOperating profit
Annual revenue · Operating profit
RevenueOperating profit
Quarterly results · Last 5 quarters
QuarterRevenueOperating profitOp. margin
2025Q3₩444.5B₩10.9B2.4%
2025Q4₩412.1B₩12.3B3.0%
2026Q1₩410.9B₩7.5B1.8%
2026Q2₩439.8B₩2.8B0.6%
2026Q3₩460.6B₩7B1.5%
Annual results
YearRevenueOperating profitNet income (parent)Op. marginROEDebt-to-equity
2022₩1.4T₩38.2B₩24.2B2.7%4.7%70.4%
2023₩1.5T₩42.1B₩37B2.8%6.8%83.3%
2024₩1.6T₩30.1B₩40.5B1.8%7.0%89.3%
2025₩1.7T₩31B₩21B1.9%3.2%85.5%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-11-13

04

Earnings analysis

On the disclosed annual basis, revenue rose from KRW 1.43 trillion in 2022 to KRW 1.51 trillion in 2023 (up 5.8%), KRW 1.64 trillion in 2024 (up 8.3%) and KRW 1.66 trillion in 2025 (up 1.1%).

Revenue has increased for three consecutive years from 2023 through 2025, and 2025 was the largest year in the 2022 to 2025 span. Operating profit peaked at KRW 42.1 billion in 2023 (up 10.0%), fell to KRW 30.1 billion in 2024 (down 28.5%), and recovered slightly to KRW 31 billion in 2025 (up 3.2%).

The operating margin slipped from 2.7% in 2022 and 2.8% in 2023 to 1.8% in 2024 and 1.9% in 2025, so sales expansion did not translate into margin expansion.

Net income attributable to parent shareholders climbed to KRW 37 billion in 2023 (up 52.9%) and KRW 40.5 billion in 2024 (up 9.5%), then dropped to KRW 21 billion in 2025 (down 48.2%). Net income including non-controlling interests fell from KRW 41.8 billion in 2024 to KRW 21.3 billion in 2025.

Operating cash flow was negative in 2023 and 2024 before turning to KRW 82.3 billion in 2025. By quarter, revenue bottomed at KRW 410.9 billion in Q1 2026 and then rose to KRW 439.8 billion in Q2 and KRW 460.6 billion in Q3, two straight quarters of growth.

Operating profit went from KRW 7.52 billion in Q1 2026 to KRW 2.82 billion in Q2 and then KRW 7.04 billion in Q3, a 149.4% rebound. Q3 revenue rose about KRW 16.1 billion year on year, but cost of sales and selling and administrative expenses rose about KRW 19.9 billion, according to Newsfc.

Pre-tax income was KRW 785 million, well below operating profit; Biotimes reported non-operating losses of about KRW 6.25 billion, and the company did not detail them in its preliminary release.

For the first nine months of 2026 (preliminary), revenue was KRW 1.31 trillion, up 5.1%, operating profit KRW 17.4 billion, down 7.1%, and net income KRW 8.7 billion, down 50.3%.

05

Industry analysis

Kwangdong Pharmaceutical's operating environment depends more on the competitive landscape of the beverage and bottled water markets than on its core pharmaceutical business.

In drinks, Vita500 and Bacchus are close in sales in the first half of 2026, and coverage expects the third quarter, the peak drink season, to shape their competitive order, according to Dailypharm. Jeju Samdasoo serves as the core item in bottled water.

Coverage has pointed out that a merchandise-centered model exposes operating profit directly to rising logistics and selling costs, according to Biotimes. Among large pharmaceutical companies, Kwangdong's third-quarter profit decline was the steepest, according to Newsfc.

R&D spending has long stayed in the 1% to 2% range of sales, according to Hansbiz, which puts the company's growth engine apart from biotech firms that rely on drug pipelines.

Coverage repeatedly describes the core pharmaceutical growth momentum as limited, so beverages and bottled water remain central to any profit recovery.

06

Outlook

The first figure to track in the disclosed results is the operating margin. The Q3 2026 margin of about 1.5% rose from about 0.6% in Q2, but remains below about 2.4% in Q3 2025, according to news reports.

Q4 2025 operating profit of KRW 12.3 billion was higher than Q3 2025's KRW 10.9 billion, so Q4 2026 will be compared against that level.

Coverage reports a focus on healthcare and anti-obesity drug development, according to Edaily, but with R&D at 1% to 2% of sales, how that direction shows up in the cost base is the open question. Whether the merchandise-heavy structure of roughly 70% of revenue shifts is another variable.

The 2026 annual business report is due by March 31, 2027 and will show the breakdown of non-operating items and the full-year operating margin. Preliminary Q4 2026 results usually come out early in the new year, and the Q1 2027 quarterly report is due by May 15, 2027. Whether the two straight quarters of revenue growth continue into Q4 is the top-line checkpoint.

07

Valuation

PER
24.8×
PBR
0.5×
ROE
2.0%
EPS
₩253
BPS
₩12,780
Dividend per share
₩100

Price-to-book sits below 1x, meaning the share price is lower than book value based on KRW 655.6 billion of equity attributable to parent shareholders. Earnings-based multiples, by contrast, look high.

Net income attributable to parent shareholders over the latest four quarters totals KRW 12.2 billion, so the same share price produces a higher multiple on a smaller earnings base.

Parent net income fell from KRW 37 billion in 2023 and KRW 40.5 billion in 2024 to KRW 21 billion in 2025, so how far earnings recover will change how the multiples read. The debt ratio was 85.5% at end-2025, lower than 89.3% in 2024 but higher than 70.4% in 2022.

The return of operating cash flow to positive territory in 2025 can be read as a financial cushion. These are relationships between the share price and reported earnings, not a judgment on valuation.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-11-13

08

Bull factors

Sustained top-line growth

Revenue has grown for three straight years from 2023 to 2025, and the first nine months of 2026 reached KRW 1.31 trillion, up 5.1% (preliminary). Quarterly revenue rose in both Q2 and Q3 2026. Jeju Samdasoo's KRW 160.5 billion in first-half 2026 sales points to the staying power of its largest item.

Recovery in cash generation

Operating cash flow turned positive at KRW 82.3 billion in 2025 after two negative years. The debt ratio fell to 85.5% at end-2025 from 89.3% a year earlier. Equity attributable to parent shareholders stood at KRW 655.6 billion at end-2025.

Quarterly operating profit rebound

Operating profit rose 149.4% from KRW 2.82 billion in Q2 2026 to KRW 7.04 billion in Q3, a quarterly recovery. The operating margin also climbed from about 0.6% to about 1.5% (preliminary). Whether the rebound extends to the KRW 12.3 billion of Q4 2025 operating profit is the test for the bullish case.

09

Bear factors

Stalled operating margin below 2%

The operating margin was 1.8% in 2024 and 1.9% in 2025, both below 2%. Operating profit for the first nine months of 2026 fell 7.1% to KRW 17.4 billion (preliminary). Coverage repeatedly points to a structure in which profit does not follow higher sales.

Merchandise-driven cost structure

About 70% of 2025 consolidated revenue was merchandise, so rising logistics and selling costs flow straight into operating profit. In Q3 2026, revenue rose about KRW 16.1 billion year on year while cost of sales and selling and administrative expenses rose about KRW 19.9 billion, according to news reports. R&D was 1.4% of sales in the first half of 2026.

Steep drop in net income

Q3 2026 parent net income was KRW 1.15 billion, down 89.3% from a year earlier. Despite KRW 7.04 billion of operating profit, pre-tax income was only KRW 785 million, and non-operating losses were reported at about KRW 6.25 billion. The company had not detailed those items in its preliminary release, according to Biotimes.

10

Risk factors

Preliminary results may change

The Q3 2026 results are preliminary and have not completed external audit review, so they may change, the company said, according to CBC News. Quarterly operating profit has swung widely, from KRW 12.3 billion in Q4 2025 to KRW 2.82 billion in Q2 2026. Given that volatility, the quarters need to be read alongside the annual trend.

Reliance on key products and drink competition

Revenue leans on Jeju Samdasoo and drink products. In the first half of 2026, Vita500 sold KRW 57.8 billion and Bacchus KRW 59.5 billion, a gap of only KRW 1.7 billion, according to Dailypharm. Because a few items drive total sales, shifts in this competition remain a risk.

Durability of cash flow and balance sheet

Operating cash flow was negative in both 2023 and 2024, and the positive 2025 result is a single year so far. The debt ratio rose from 70.4% in 2022 to 89.3% in 2024 before easing to 85.5% in 2025. Whether cash flow holds at this level is the open question.

11

What to watch next

  1. Early 2027 (timing expected)

    Preliminary Q4 2026 results. The comparison of Q4 operating profit with KRW 12.3 billion in Q4 2025, and whether the operating margin moves beyond the 1% range, are the points to watch.

  2. By March 31, 2027

    The deadline for the 2026 annual business report. It will show the breakdown of non-operating items, the full-year 2026 operating margin, and any gap between preliminary and final figures.

  3. By May 15, 2027

    The deadline for the Q1 2027 quarterly report. It will allow comparison with KRW 7.52 billion of operating profit in Q1 2026, along with R&D as a share of sales and operating cash flow trends.

12

Overall view

Kwangdong Pharmaceutical's revenue rose from KRW 1.43 trillion in 2022 to KRW 1.66 trillion in 2025, growing for three straight years since 2023. Over the same period, the operating margin fell from 2.7% to 1.9%, and operating profit dropped 28.5% in 2024.

Revenue for the first nine months of 2026 reached KRW 1.31 trillion, up 5.1%, while cumulative operating profit fell 7.1% to KRW 17.4 billion (preliminary). Operating profit rebounded 149.4% from Q2 to Q3 2026, but parent net income of KRW 1.15 billion was down 89.3% year on year.

Coverage cites the merchandise-centered model and non-operating losses as factors amplifying earnings swings. Strengths include the return to positive operating cash flow in 2025 and a lower debt ratio, while weaknesses include the low operating margin and limited R&D spending.

The share price sits below book value attributable to parent shareholders, while earnings-based multiples look high because profit has shrunk. The next checkpoints are the non-operating breakdown in the 2026 annual business report and the operating margin in the Q1 2027 quarterly report.

13

Sources

  1. Korea Exchange (KRX) — Prices · Market Cap · Volume
  2. FSS electronic disclosure system (DART) — Financial statements · Dividend filings
Show 18 more articles and sources
  1. kormedi.com
  2. kpanews.co.kr
  3. vegannews.co.kr
  4. asiatoday.co.kr
  5. insight.co.kr
  6. biotimes.co.kr
  7. medipana.com
  8. newsfc.co.kr
  9. thebionews.net
  10. cbci.co.kr
  11. ssl.pstatic.net
  12. m.edaily.co.kr
  13. pharm.edaily.co.kr
  14. docdocdoc.co.kr
  15. hansbiz.co.kr
  16. m.dailypharm.com
  17. newsthevoice.com
  18. thinkfood.co.kr

Report written 2026-11-14 · Data as of 2026-11-13

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.

Other reports in this industry

View industry analysis